Antiviral treatment causes a unique mutational signature in cancers of transplantation recipients.

antiviral treatment cancer genomics cytomegalovirus ganciclovir hematopoietic stem cell transplantation mutational signatures somatic mutations therapy-related neoplasms

Journal

Cell stem cell
ISSN: 1875-9777
Titre abrégé: Cell Stem Cell
Pays: United States
ID NLM: 101311472

Informations de publication

Date de publication:
07 10 2021
Historique:
received: 11 01 2021
revised: 11 06 2021
accepted: 29 07 2021
pubmed: 9 9 2021
medline: 26 10 2021
entrez: 8 9 2021
Statut: ppublish

Résumé

Genetic instability is a major concern for successful application of stem cells in regenerative medicine. However, the mutational consequences of the most applied stem cell therapy in humans, hematopoietic stem cell transplantation (HSCT), remain unknown. Here we characterized the mutation burden of hematopoietic stem and progenitor cells (HSPCs) of human HSCT recipients and their donors using whole-genome sequencing. We demonstrate that the majority of transplanted HSPCs did not display altered mutation accumulation. However, in some HSCT recipients, we identified multiple HSPCs with an increased mutation burden after transplantation. This increase could be attributed to a unique mutational signature caused by the antiviral drug ganciclovir. Using a machine learning approach, we detected this signature in cancer genomes of individuals who received HSCT or solid organ transplantation earlier in life. Antiviral treatment with nucleoside analogs can cause enhanced mutagenicity in transplant recipients, which may ultimately contribute to therapy-related carcinogenesis.

Identifiants

pubmed: 34496298
pii: S1934-5909(21)00337-4
doi: 10.1016/j.stem.2021.07.012
pmc: PMC8516432
pii:
doi:

Substances chimiques

Antiviral Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1726-1739.e6

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests A.R.H., A.v.L., and R.v.B. are named as inventors on a patent application filed resulting from this work.

Références

Nat Commun. 2016 May 02;7:11383
pubmed: 27136393
N Engl J Med. 2018 Oct 11;379(15):1393-1395
pubmed: 30110242
Science. 2002 Jun 28;296(5577):2410-3
pubmed: 12089448
Nature. 2018 Sep;561(7724):473-478
pubmed: 30185910
Bone Marrow Transplant. 2016 Jun;51(6):786-92
pubmed: 26901709
Leukemia. 2016 Sep;30(9):1916-1920
pubmed: 26975880
Sci Transl Med. 2016 Apr 20;8(335):335ra57
pubmed: 27099176
J Clin Invest. 2008 Sep;118(9):3132-42
pubmed: 18688285
Stem Cell Reports. 2017 Jul 11;9(1):1-4
pubmed: 28700896
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
Cell. 2016 Nov 17;167(5):1145-1149
pubmed: 27863232
Nat Commun. 2020 Mar 23;11(1):1528
pubmed: 32251294
Nature. 2014 Sep 18;513(7518):422-425
pubmed: 25043003
Nat Protoc. 2018 Jan;13(1):59-78
pubmed: 29215633
Nature. 2016 Oct 13;538(7624):260-264
pubmed: 27698416
Cell Stem Cell. 2021 Jan 7;28(1):173
pubmed: 33433329
Blood. 2011 Apr 28;117(17):4460-6
pubmed: 21343613
Bioinformatics. 2010 Mar 1;26(5):589-95
pubmed: 20080505
Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17462-7
pubmed: 25422422
Cell. 2000 Jan 7;100(1):157-68
pubmed: 10647940
Nat Commun. 2019 Jul 5;10(1):2969
pubmed: 31278357
Clin Microbiol Infect. 2000 Mar;6(3):117-20
pubmed: 11168085
Genome Biol. 2018 Sep 10;19(1):129
pubmed: 30201020
Science. 2018 Jan 12;359(6372):
pubmed: 29326244
Nature. 2014 Oct 16;514(7522):322-7
pubmed: 25296256
Nature. 2020 Apr;580(7802):269-273
pubmed: 32106218
Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1492-7
pubmed: 9990051
Science. 2016 Nov 4;354(6312):618-622
pubmed: 27811275
Cell. 2005 Feb 25;120(4):497-512
pubmed: 15734682
Cell Rep. 2018 Nov 27;25(9):2308-2316.e4
pubmed: 30485801
Am J Vet Res. 2004 Apr;65(4):399-403
pubmed: 15077679
Science. 2013 Aug 23;341(6148):1233151
pubmed: 23845947
Nucleic Acids Res. 2018 Jan 4;46(D1):D794-D801
pubmed: 29126249
J Clin Invest. 2008 Sep;118(9):3143-50
pubmed: 18688286
Antiviral Res. 2018 Jun;154:66-86
pubmed: 29649496
Curr Opin Infect Dis. 2014 Dec;27(6):554-9
pubmed: 25304390
Clin Transpl. 2010;:87-105
pubmed: 21696033
Blood Adv. 2021 Feb 9;5(3):900-912
pubmed: 33560403
Nat Genet. 2011 May;43(5):491-8
pubmed: 21478889
Cell Stem Cell. 2016 Jul 7;19(1):107-19
pubmed: 27237736
Sci Rep. 2017 Jun 27;7(1):4310
pubmed: 28655934
Nature. 2019 Nov;575(7781):210-216
pubmed: 31645765
Cell Stem Cell. 2020 Oct 1;27(4):523-531
pubmed: 33007237
Blood. 2018 Apr 19;131(16):1846-1857
pubmed: 29311096
Bone Marrow Transplant. 2016 Aug;51(8):1025-31
pubmed: 27064688
Cell Rep. 2019 May 14;27(7):2022-2028.e3
pubmed: 31091442
N Engl J Med. 2017 Mar 16;376(11):1038-1046
pubmed: 28296613
N Engl J Med. 2019 Sep 26;381(13):1240-1247
pubmed: 31509667
Nature. 2020 Jul;583(7815):265-270
pubmed: 32581361
Cell Stem Cell. 2016 Feb 4;18(2):253-61
pubmed: 26669899
Blood. 2020 Apr 30;135(18):1548-1559
pubmed: 32181816
Biol Blood Marrow Transplant. 2013 Oct;19(10):1498-501
pubmed: 23906634
Cell. 2019 May 2;177(4):821-836.e16
pubmed: 30982602
Am J Med. 1992 Feb 14;92(2A):3S-7S
pubmed: 1371038
Genome Med. 2018 Apr 25;10(1):33
pubmed: 29695279
Nat Commun. 2020 Jun 12;11(1):2996
pubmed: 32533060
Nucleic Acids Res. 2019 Jan 8;47(D1):D766-D773
pubmed: 30357393
Expert Rev Hematol. 2011 Aug;4(4):437-52; quiz 453-4
pubmed: 21801135
J Vis Exp. 2019 Jul 11;(149):
pubmed: 31355782
Sci Rep. 2020 Jul 31;10(1):12991
pubmed: 32737409
Cell. 2016 Jan 28;164(3):538-49
pubmed: 26806129
Leukemia. 2020 Dec;34(12):3256-3268
pubmed: 32203146
Nature. 2021 May;593(7859):405-410
pubmed: 33911282
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Free Radic Biol Med. 2017 Jun;107:179-201
pubmed: 27903453
Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1447-1456
pubmed: 30622181
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Stem Cell Reports. 2020 Aug 11;15(2):279-291
pubmed: 32783925
Nat Med. 2018 Nov;24(11):1683-1690
pubmed: 30275570
N Engl J Med. 2014 Dec 25;371(26):2488-98
pubmed: 25426837
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Nat Commun. 2020 May 19;11(1):2493
pubmed: 32427826
Brief Bioinform. 2013 Mar;14(2):178-92
pubmed: 22517427
Nature. 2020 Oct;586(7831):763-768
pubmed: 33057201
N Engl J Med. 2018 Dec 13;379(24):2330-2341
pubmed: 30380364

Auteurs

Jurrian K de Kanter (JK)

Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, Utrecht 3584 CS, the Netherlands; Oncode Institute, Jaarbeursplein 6, 3521 AL Utrecht, the Netherlands.

Flavia Peci (F)

Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, Utrecht 3584 CS, the Netherlands; Oncode Institute, Jaarbeursplein 6, 3521 AL Utrecht, the Netherlands.

Eline Bertrums (E)

Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, Utrecht 3584 CS, the Netherlands; Oncode Institute, Jaarbeursplein 6, 3521 AL Utrecht, the Netherlands; Department of Pediatric Oncology/Hematology, Erasmus Medical Center, Rotterdam 3015 GD, the Netherlands.

Axel Rosendahl Huber (A)

Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, Utrecht 3584 CS, the Netherlands; Oncode Institute, Jaarbeursplein 6, 3521 AL Utrecht, the Netherlands.

Anaïs van Leeuwen (A)

Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, Utrecht 3584 CS, the Netherlands; Oncode Institute, Jaarbeursplein 6, 3521 AL Utrecht, the Netherlands.

Markus J van Roosmalen (MJ)

Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, Utrecht 3584 CS, the Netherlands; Oncode Institute, Jaarbeursplein 6, 3521 AL Utrecht, the Netherlands.

Freek Manders (F)

Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, Utrecht 3584 CS, the Netherlands; Oncode Institute, Jaarbeursplein 6, 3521 AL Utrecht, the Netherlands.

Mark Verheul (M)

Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, Utrecht 3584 CS, the Netherlands; Oncode Institute, Jaarbeursplein 6, 3521 AL Utrecht, the Netherlands.

Rurika Oka (R)

Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, Utrecht 3584 CS, the Netherlands; Oncode Institute, Jaarbeursplein 6, 3521 AL Utrecht, the Netherlands.

Arianne M Brandsma (AM)

Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, Utrecht 3584 CS, the Netherlands; Oncode Institute, Jaarbeursplein 6, 3521 AL Utrecht, the Netherlands.

Marc Bierings (M)

Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, Utrecht 3584 CS, the Netherlands; Paediatric Blood and Marrow Transplant Program, University Medical Center Utrecht, Utrecht, Netherlands.

Mirjam Belderbos (M)

Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, Utrecht 3584 CS, the Netherlands; Oncode Institute, Jaarbeursplein 6, 3521 AL Utrecht, the Netherlands. Electronic address: m.e.belderbos@prinsesmaximacentrum.nl.

Ruben van Boxtel (R)

Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, Utrecht 3584 CS, the Netherlands; Oncode Institute, Jaarbeursplein 6, 3521 AL Utrecht, the Netherlands. Electronic address: r.vanboxtel@prinsesmaximacentrum.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH